leadf
logo-loader
RNS
viewIconic Labs PLC

Iconic Labs PLC - Alleged Claim made by EHGOF

RNS Number : 7541L
Iconic Labs PLC
14 January 2021
 

 

 

 

 

Iconic Labs Plc ("Iconic Labs" or the "Company")

 

Alleged Claim made by European High Growth Opportunities Securitization Fund

 

Iconic Labs Plc (LSE:ICON), a multidivisional new media and technology business, today announces that it has been served with a claim form from European High Growth Opportunities Securitization Fund ("EHGOF").  EHGOF has filed the claim in the High Court in London, but has yet to file particulars of claim setting out the exact nature of its claim, and therefore the Company is unable to respond or comment in any detail on the claim until such time as EHGOF files the necessary documentation to evidence its alleged claim.

 

Notwithstanding the above, the Company assumes that the claim may be being made in respect of amounts that are allegedly due to EHGOF under specific loan notes, although the claim form makes no reference to these loan notes, instead referring to agreements with EHGOF that were, against the wishes of EHGOF, unilaterally and validly terminated by the Company last year. The Company reserves its position at this time on the merits of the alleged claim pending receipt of fully particularised Particulars of Claim and a full investigation of the claim.

 

The Company has also kept Greencastle Capital ("Greencastle") appraised of this development, and Greencastle has informed the Company that while Greencastle is monitoring the situation carefully, it does not consider that there are yet grounds upon which it might seek to terminate either of the management services agreements that exist between Greencastle Capital and the Company, and which are in respect of the JOE Media and TheLondonEconomic businesses.

 

The Company notes that discussions had taken place during the course of the last year with Alpha Blue Ocean ("ABO"), the investment manager of EHGOF, as to a settlement of the amounts due under the loan notes, with the Company believing that an agreement in principle had been reached.  However, since December 2020, ABO reneged on that agreement in principle and to date ABO has refused to propose any practical alternative agreement or enter into meaningful discussions with the Company.

 

The Company will update the market in due course.

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

**ENDS**

For further information, please visit the Company's website www.iconiclabs.co.uk or contact:

Damon Heath

Shard Capital Partners LLP

Tel: +44 (0) 20 7186 9950

Iconic Labs ir@iconiclabs.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKQBDQBKDPDD

Quick facts: Iconic Labs PLC

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Capital Network's Riccardo Lowi talks talks through Widecells Group PLC

Riccardo Lowi, healthcare analyst at Capital Network discusses how Widecells Group Plc provides Stem cells services.

on 5/12/17

4 min read